MedImmune, the global biologics R&D arm of AstraZeneca, has acquired Spirogen in a deal worth up to US $440 million. Spirogen is a privately-held biotech focused on antibody-drug conjugate ...

AstraZeneca's global biologics research and development arm, MedImmune, has completed its acquisition of Amplimmune, in a deal worth up to US $500 million. Amplimmune is a US-based biologics ...

Palivizumab (Synagis; MedImmune/Abbott) is a humanized murine monoclonal antibody against the RSV fusion protein that prevents the spread of virus to the lower respiratory tract 2. It was approved ...

Maryland’s biotech industry plays a pivotal role in advancing global health initiatives. This vibrant sector is characterized ...

Executive Vice President, R&D, MedImmune, Gaithersburg, Maryland, USA. Prior to joining Medimmune in 2001, Peter Kiener, D. Phil., spent 18 years with the Pharmaceutical Research Division of ...